Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-Line Immune Combination Therapies for Nonclear Cell Versus Clear Cell Metastatic Renal Cell Carcinoma: Real-World Multicenter Data From Germany.
Cano Garcia C, Hoeh B, Mandal S, Banek S, Klümper N, Schmucker P, Hahn O, Mattigk A, Ellinger J, Cox A, Becker P, Zeuschner P, Zengerling F, Erdmann K, Buerk BT, Kalogirou C, Flegar L. Cano Garcia C, et al. Among authors: erdmann k. Clin Genitourin Cancer. 2024 Aug;22(4):102112. doi: 10.1016/j.clgc.2024.102112. Epub 2024 May 4. Clin Genitourin Cancer. 2024. PMID: 38825563 Free article.
Adjuvant therapy with pembrolizumab in renal cell carcinoma: real-world experiences from a retrospective, multi-institutional cohort.
Mattigk A, Cano Garcia C, Klümper N, Cox A, Hahn O, Junker K, Erdmann K, Schmucker P, Flegar L, Zengerling F, Banek S, Ellinger J, Buerk BT, Huber J, Kalogirou C, Zeuschner P, Hoeh B. Mattigk A, et al. Among authors: erdmann k. Urol Int. 2024 Dec 24:1-21. doi: 10.1159/000543278. Online ahead of print. Urol Int. 2024. PMID: 39719131
Early CRP kinetics to predict long-term efficacy of first-line immune-checkpoint inhibition combination therapies in metastatic renal cell carcinoma: an updated multicentre real-world experience applying different CRP kinetics definitions.
Hoeh B, Garcia CC, Banek S, Klümper N, Cox A, Ellinger J, Schmucker P, Hahn O, Mattigk A, Zengerling F, Becker P, Erdmann K, Buerk BT, Flegar L, Huber J, Kalogirou C, Zeuschner P. Hoeh B, et al. Among authors: erdmann k. Clin Transl Immunology. 2023 Oct 25;12(10):e1471. doi: 10.1002/cti2.1471. eCollection 2023. Clin Transl Immunology. 2023. PMID: 37899949 Free PMC article.
Early kinetics of C-reactive protein as prognosticator for survival in a real-world cohort of patients with metastatic renal cell cancer under first-line therapy with immune checkpoint inhibitors.
Schüttke V, Kusiek C, Fuessel S, Thomas C, Buerk BT, Erdmann K. Schüttke V, et al. Among authors: erdmann k. Clin Transl Oncol. 2024 May;26(5):1117-1128. doi: 10.1007/s12094-023-03317-z. Epub 2023 Sep 11. Clin Transl Oncol. 2024. PMID: 37695463 Free PMC article.
Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant.
Wimberger P, Gerber MJ, Pfisterer J, Erdmann K, Füssel S, Link T, du Bois A, Kommoss S, Heitz F, Sehouli J, Kimmig R, de Gregorio N, Schmalfeldt B, Park-Simon TW, Baumann K, Hilpert F, Grube M, Schröder W, Burges A, Belau A, Hanker L, Kuhlmann JD. Wimberger P, et al. Among authors: erdmann k. Clin Cancer Res. 2022 Nov 1;28(21):4660-4668. doi: 10.1158/1078-0432.CCR-22-1326. Clin Cancer Res. 2022. PMID: 36001383
143 results